Literature DB >> 26304580

Duration of antiplatelet therapy cessation before coronary artery bypass surgery: Relation with platelet count.

Sushil Prakash Ambesh1, Paurush Ambesh2, Shantanu Pande3, Aditya Kapoor4.   

Abstract

As of now, no study or data is available to determine the period of discontinuation of antiplatelet therapy and the timing of elective surgery in clopidogrel treated patients. The 2011 ACCF/AHA Guidelines have a Class-I recommendation for withdrawing clopidogrel for 5 days before elective coronary artery bypass grafting. However, 5 days period may not suit all patients as platelet count varies from 150 × 10(9)/L to 450 × 10(9)/L. Based on our retrospective data analysis, we have proposed a hypothesis to determine no of days of discontinuation of antiplatelet therapy while taking in consideration the basal count and life-span of platelets.
Copyright © 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiplatelet therapy; Aspirin; Clopidogrel; Coronary artery bypass grafting; Platelets

Mesh:

Substances:

Year:  2015        PMID: 26304580      PMCID: PMC4561796          DOI: 10.1016/j.ihj.2015.05.013

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  7 in total

1.  Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Hirsh; Gordon Guyatt; Gregory W Albers; Robert Harrington; Holger J Schünemann
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 2.  Guideline on antiplatelet and anticoagulation management in cardiac surgery.

Authors:  Joel Dunning; Michel Versteegh; Alessandro Fabbri; Alain Pavie; Philippe Kolh; Ulf Lockowandt; Samer A M Nashef
Journal:  Eur J Cardiothorac Surg       Date:  2008-03-28       Impact factor: 4.191

3.  2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; James Patrick Zidar
Journal:  J Am Coll Cardiol       Date:  2011-05-10       Impact factor: 24.094

Review 4.  Antiplatelet drugs: a review of their pharmacology and management in the perioperative period.

Authors:  Richard Hall; C David Mazer
Journal:  Anesth Analg       Date:  2011-01-06       Impact factor: 5.108

5.  Acetylation of prostaglandin synthase by aspirin.

Authors:  G J Roth; N Stanford; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

6.  Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

Authors:  N A Farid; C D Payne; D S Small; K J Winters; C S Ernest; J T Brandt; C Darstein; J A Jakubowski; D E Salazar
Journal:  Clin Pharmacol Ther       Date:  2007-03-14       Impact factor: 6.875

7.  Inhibition of platelet prostaglandin synthetase by oral aspirin.

Authors:  J W Burch; N Stanford; P W Majerus
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.